EDMONTON, AB, April 20, 2026 /PRNewswire/ - Nanostics Inc., a precision health company advancing diagnostic innovation through its ClarityDX (R) platform, today announced the publication of a ...
An exploration of how targeted nanoparticles and artificial intelligence algorithms combine to locate prostate cancer earlier ...
Radium-223 retains a role in osteoblastic bone-only disease, while PSMA PET has become indispensable across staging, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results